Affordability

R&D costs are minimal because generics don't need to prove a drug works; that's already been done by the original brand. They only need to show their version behaves the same way in the body.

Made up mostly of bioequivalence studies (small trials that compare absorption rates), regulatory filing fees, and IP litigation costs if a brand patent needs to be challenged. Total development runs $1.5–4M per drug.

¹ PhRMA / Pharmaceutical Technology — generic development cost benchmarks

Manufacturing is the biggest cost for generic makers because it's essentially their entire product — they're not spending on discovery, just production. Thin margins mean efficiency here is critical.

Primarily the active pharmaceutical ingredient (API — the chemical that does the work), excipients (fillers, binders), tablet pressing or capsule filling, packaging, and quality testing. Most APIs are sourced from manufacturers in India and China.

³ BCG — Getting a Grip on COGS in Generic Drugs, 2019

Generic drugs are cheap, which means each step in the supply chain takes a much bigger percentage cut than it would for a high-priced brand drug. Intermediaries end up keeping more of the pie than the manufacturer does.

Covers wholesalers (who buy from manufacturers and sell to pharmacies), pharmacy dispensing costs, and freight. Wholesalers, pharmacies, and PBMs collectively capture roughly 64% of the final retail revenue on generics — vs. only ~24% for brand drugs.

⁵ DrugPatentWatch / USC Schaeffer / HHS ASPE — generic supply chain value capture

⁶ NCBI / MedPAC — Profit Margins of Pharmaceutical Supply Chain Entities, 2020–2022

Generics carry lower rebates because insurers don't need to negotiate hard — generic prices are already low, and competition between multiple manufacturers keeps them that way.

Includes Medicaid rebates (13% of average manufacturer price, set by law), PBM administrative fees, and pharmacy claims processing costs. There's minimal negotiation overhead since pharmacies often substitute generics automatically.

⁹ Commonwealth Fund — What PBMs Do, 2025

¹⁰  KFF — 5 Key Facts About Medicaid Prescription Drugs

Generic companies spend very little on marketing (doctors don't need to be persuaded to prescribe a generic) but face intense price competition, so profit margins per unit are thin and depend heavily on volume.

SG&A includes sales force costs, general administration, and legal expenses (especially patent challenges). Teva, the largest generic manufacturer, runs sales & marketing at ~12–16% of revenue and G&A at ~11%. Profit margins of 30–50% on cost of goods are achievable at scale, but net margins are modest.

¹¹ Teva SEC filings 8-K, 2023–2024

Biosimilars are copies of biologic drugs made from living cells, which are far harder to replicate exactly. Regulators require clinical trials to confirm the copy is safe and effective, driving up costs significantly.

Costs include Phase I and Phase III clinical trials, extensive analytical testing to confirm the molecule matches the original, and regulatory submissions. Average development cost is ~$375M per biosimilar.

¹ PhRMA / Pharmaceutical Technology — generic development cost benchmarks

Biosimilars are grown in living cells (bacteria, yeast, or mammalian cells), which makes manufacturing far more complex and expensive than mixing chemicals. Even small process changes can affect the final product.

Costs include bioreactor cell culture, purification, fill-and-finish (sterile packaging), cold-chain storage, and extensive quality release testing. At commercial scale, modern manufacturing tech can reduce unit costs by up to 70%.

¹ PhRMA / Pharmaceutical Technology — generic development cost benchmarks

⁴ BCG — Strategic Approach to Cost in Biopharma, 2023

Biosimilars are injectable or infused drugs that go through specialty pharmacies and hospital systems — fewer middlemen than retail generics, but more complex handling requirements.

Includes cold-chain transportation and storage (most biologics must be refrigerated), specialty pharmacy dispensing, and hub services (the patient support programs that help with insurance navigation and delivery). Wholesaler margins on biologics run ~1.8–3.3% of net spending.

⁶ NCBI / MedPAC — Profit Margins of Pharmaceutical Supply Chain Entities, 2020–2022

Biosimilars face a paradox: they're cheaper than the brand drugs they copy, but that lower price actually makes it harder to get onto insurance formularies. PBMs earn rebates as a percentage of list price, so they often prefer the more expensive branded drug because it generates a bigger rebate for them.

Biosimilar/originator drug pairs had the highest average rebates of any drug category in 2023 — a median of 71% off list price — largely because of this competitive dynamic. Manufacturer rebates, PBM fees, and prior authorization administrative costs all fall in this bucket.

⁷ PMC / SSR Health — specialty rebate analysis, n=161 drugs, Dec 2023

⁸ DrugPatentWatch — gross-to-net bubble, 2024

Biosimilar companies spend more on sales than generic makers (they need to convince doctors and hospitals to switch from the brand), but less than specialty innovators who are launching entirely new drugs.

Includes medical affairs teams (educating clinicians on interchangeability), market access teams (negotiating payer coverage), and general overhead. Because biosimilars are priced lower than the originator, profit margins are tighter and depend on winning significant market share.

² Drug Discovery Trends — biosimilar company financials, 2023

¹¹ Teva SEC filings 8-K, 2023–2024

Specialty drugs treat complex, often rare conditions and must be discovered from scratch: a long, expensive process with a high failure rate. Only about 1 in 10 drugs that enter clinical trials ever makes it to market.

Covers all phases of clinical trials (Phase I–III), pre-clinical research, and regulatory approval. Average cost per approved specialty drug exceeds $1.2B. Large pharma companies typically spend 14–30% of their total revenue on R&D across their portfolio.

¹ PhRMA / Pharmaceutical Technology — generic development cost benchmarks

Specialty drugs are expensive to make in absolute terms, but because their prices are so high, manufacturing represents a smaller slice of the total cost pie than you'd expect.

Includes biological production (for biologics), sterile drug formulation, specialized packaging, and rigorous QA testing. For cell and gene therapies, manufacturing can cost tens of thousands of dollars per patient dose alone. Unit economics improve dramatically with volume — costs fall ~30% each time production volume doubles.

⁴ BCG — Strategic Approach to Cost in Biopharma, 2023

Because specialty drugs are so expensive, the supply chain cost is a small percentage even though the absolute dollar cost per shipment is high. The high price dilutes the relative weight of logistics.

Specialty drugs typically flow through dedicated specialty pharmacies (not regular retail pharmacies), and often require temperature-controlled shipping, limited distribution networks, and mandatory patient monitoring programs. These add real cost, but remain a small fraction of the drug's total price.

⁶ NCBI / MedPAC — Profit Margins of Pharmaceutical Supply Chain Entities, 2020–2022

Specialty drugs are where the rebate system is most extreme. Manufacturers set very high list prices, then pay large secret rebates to PBMs and insurers to secure formulary placement — meaning the sticker price almost never reflects what anyone actually pays.

The gap between what's listed and what's actually paid ("gross-to-net") reached an estimated $356B across all brand drugs in 2024. The median specialty drug rebate was 27% off list price in 2023, but varied widely (16–53%). PBMs pass roughly 91% of negotiated rebates back to health insurers. Brand drug Medicaid rebates start at ≥23.1% of average manufacturer price by law.

⁷ PMC / SSR Health — specialty rebate analysis, n=161 drugs, Dec 2023

⁸ DrugPatentWatch — gross-to-net bubble, 2024

⁹ Commonwealth Fund — What PBMs Do, 2025

¹⁰  KFF — 5 Key Facts About Medicaid Prescription Drugs

Specialty drug companies spend heavily on sales and marketing to build awareness among the specialists who prescribe these drugs, and on patient support programs. Despite high gross margins, large rebates compress how much revenue they actually keep.

Includes specialist sales forces, direct-to-consumer advertising (where allowed), patient assistance programs, and corporate overhead. AbbVie and Sanofi — two of the largest specialty drug makers — have combined R&D and SG&A that together consume 30–50% of revenue. Operating margins of 25–40% on net revenue are common for top-selling specialty drugs.

² Drug Discovery Trends — AbbVie, Sanofi, Novo Nordisk financials, 2023

⁸ DrugPatentWatch — specialty drug economics, 2024